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www.jacc-interventions.org to view.Development and Validation of a Novel Scoring System for Predicting Technical Success
of Chronic Total Occlusion Percutaneous Coronary Interventions: The PROGRESS CTO
(Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score1Georgios Christopoulos, David E. Kandzari, Robert W. Yeh, Farouc A. Jaffer,
Dimitri Karmpaliotis, Michael R. Wyman, Khaldoon Alaswad, William Lombardi,
J. Aaron Grantham, Jeffrey Moses, Georgios Christakopoulos, MuhammadNauman J. Tarar,
Bavana V. Rangan, Nicholas Lembo, Santiago Garcia, Daisha Cipher, Craig A. Thompson,
Subhash Banerjee, Emmanouil S. BrilakisThe authors developed a novel score for predicting technical success of chronic total occlusion (CTO)
percutaneous coronary intervention (PCI), using clinical and angiographic parameters from 781 CTO
PCIs included in PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total
Occlusion Intervention). Factors associated with technical success included proximal cap ambiguity,
moderate/severe tortuosity, circumﬂex artery CTO, and absence of “interventional” collaterals. The
resulting score demonstrated good calibration and discriminatory capacity and performed similar to
the J-CTO (Multicenter Chronic Total Occlusion Registry in Japan) score in predicting technical
success (receiver operator characteristic ¼ area 0.720 vs. 0.746, area under curve difference ¼
0.026, 95% conﬁdence interval ¼ 0.093 to 0.144).n EDITORIAL COMMENT
Progress in Predicting Chronic Total Occlusion Recanalization 10
Wissam Jaber, Habib Samady
Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB
Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis12Michael J. Lipinski, Ricardo O. Escarcega, Nevin C. Baker, Hadiya A. Benn,
Michael A. Gaglia, Jr., Rebecca Torguson, Ron WaksmanThe authors performed a systematic review and meta-analysis to assess outcomes after implantation of
the ABSORB bioresorbable vascular scaffold (BVS) and compared with drug-eluting stent placement.
Of 25 studies with 8,351 patients undergoing BVS implantation, cardiovascular death occurred in
0.6%, myocardial infarction in 2.1%, target lesion revascularization in 2.0%, and deﬁnite/probable
scaffold thrombosis in 1.2% of patients over 6.4  5.1 months of follow-up. Meta-analysis
demonstrated that patients who received a BVS were at a 2-fold higher risk of myocardial infarction
(p ¼ 0.002) and deﬁnite/probable scaffold thrombosis (p ¼ 0.03) compared with patients who
received drug-eluting stents. Further studies are needed to assess whether a BVS increases the risk
of scaffold thrombosis.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Who Is Thrombogenic: The Scaffold or the Doctor? Back to the Future! 25
Antonio Colombo, Neil Ruparelia
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JANUARY 11, 2016 VOLUME 9, NUMBER 1Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary
Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of
Randomized Controlled Trials28Usman Baber, Gennaro Giustino, Samantha Sartori, Melissa Aquino, Giulio G. Stefanini,
P. Gabriel Steg, Stephan Windecker, Martin B. Leon, William Wijns, Patrick W. Serruys,
Marco Valgimigli, Gregg W. Stone, George D. Dangas, Marie-Claude Morice,
Edoardo Camenzind, Giora Weisz, Pieter C. Smits, David Kandzari, Clemens Von Birgelen,
Ioannis Mastoris, Soren Galatius, Raban V. Jeger, Takeshi Kimura, Ghada W. Mikhail,
Dipti Itchhaporia, Laxmi Mehta, Rebecca Ortega, Hyo-Soo Kim, Adnan Kastrati,
Alaide Chieffo, Roxana MehranThe prevalence and effect of chronic kidney disease (CKD) in women undergoing percutaneous
coronary intervention (PCI) with drug-eluting stents (DES) is unclear. The authors pooled patient-
level data (n ¼ 10,449) from 26 randomized controlled trials evaluating safety and efﬁcacy of
DES. A signiﬁcant stepwise gradient in major adverse cardiovascular event (MACE) rates was
observed with worsening renal function (26.6% for creatinine clearance [CrCl] <45 ml/min vs.
15.8% for CrCl 45 to 59 ml/min vs. 12.9% for CrCl $60 ml/min; p < 0.01). Following
multivariable adjustment, CrCl <45 ml/min was independently associated with a higher risk of
MACE and all-cause mortality. Use of new-generation DES was associated with reduced risk of
cardiac death, MI, or stent thrombosis compared with early-generations in women with CKD.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
The Importance of Subgroup Analysis in Drug-Eluting Stent Trials 39
J. Dawn Abbott
A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting
Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With
Diabetes Mellitus: The RESERVOIR Clinical Trial42Rafael Romaguera, Joan A. Gómez-Hospital, Josep Gomez-Lara, Salvatore Brugaletta,
Eduardo Pinar, Pilar Jiménez-Quevedo, Montserrat Gracida, Gerard Roura,
Jose L. Ferreiro, Luis Teruel, Eduard Montanya, Antonio Fernandez-Ortiz,
Fernando Alfonso, Marco Valgimigli, Manel Sabate, Angel CequierThis was a multicenter, randomized, noninferiority trial that aimed to compare a novel polymer-free
sirolimus-eluting stent with an everolimus-eluting stent in patients with diabetes mellitus. The
primary endpoint was the neointimal volume obstruction at 9-month follow-up assessed by optical
coherence tomography. A total of 116 lesions in 112 patients were randomized. The primary
noninferiority endpoint was met (p ¼ 0.0003), and subgroup analyses showed a signiﬁcant
reduction of neointimal hyperplasia with the novel polymer-free stent in the subgroup of patients
with the worst metabolic control.
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Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes
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Gerhard C. Schuler, Karl E. Hauptmann, Marco A. Magalhães, Helen Parise,
Eberhard Grube, for the BioFreedom FIM Clinical Trial InvestigatorsThe BioFreedom (BFD) drug-coated stent incorporates a low-proﬁle, stainless-steel platform with a
surface that has been modiﬁed to create a selectively microstructured abluminal surface that allows
adhesion and further release of Biolimus A9 (Biosensors Europe SA, Morges, Switzerland). A total of
182 patients were randomized (1:1:1) for treatment with BFD “standard dose” or BFD “low dose”
versus ﬁrst-generation paclitaxel-eluting stents (PES). At 12 months, in-stent late lumen loss
(primary endpoint) was 0.17 mm in BFD versus 0.35 mm in PES (p ¼ 0.001 for noninferiority);
however, BFD-LD (0.22 mm) did not reach noninferiority. At 5 years, major adverse cardiac events
were similar; also, there was no deﬁnite/probable stent thrombosis reported.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
The Quest for the Perfect Stent for a Given Patient: Drug-Coated Stents for the
Treatment of Coronary Disease65Marie-Claude Morice, Fadi J. SawayaSTRUCTURAL Prospective Multicenter Evaluation of the Direct Flow Medical Transcatheter Aortic
Valve System: 12-Month Outcomes of the Evaluation of the Direct Flow Medical
Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe
Aortic Stenosis (DISCOVER) Study68Thierry Lefèvre, Antonio Colombo, Didier Tchétché, Azeem Latib, Silvio Klugmann,
Jean Fajadet, Federico De Marco, Francesco Maisano, Giuseppe Bruschi,
Klaudija Bijuklic, Stefano Nava, Neil Weissman, Reginald Low, Martyn Thomas,
Christopher Young, Simon Redwood, Michael Mullen, John Yap, Eberhard Grube,
Georg Nickenig, Jan-Malte Sinning, Karl Eugen Hauptmann, Ivar Friedrich,
Michael Lauterbach, Michael Schmoeckel, Charles Davidson, Joachim SchoferThe Direct Flow Medical transcatheter heart valve is a new-generation nonmetallic aortic valve with
a pressurized support structure and conformable double-ring annular sealing delivered through an
18-F sheath. The device allows assessment of valve performance before permanent implantation.
The 1-year outcome of this European registry of 100 consecutive patients with severe aortic
stenosis contraindicated or too high risk for surgery shows 90% freedom from death and 85%
freedom from death or stroke. Echocardiography demonstrated none/trace to mild aortic
regurgitation in all patients and an unchanged mean aortic gradient of 12.2  6.6 mm Hg and
effective oriﬁce area of 1.6  0.4 cm2.
SEE ADDITIONAL CONTENT ONLINEn EDITORIAL COMMENT
Next Generation Valves: What Are We Looking for? 76
E. Murat Tuzcu, Samir R. Kapadia
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A Value Comparison79Yinn Khurn Ooi, Michael Kelleman, Alexandra Ehrlich, Michelle Glanville, Arlene Porter,
Dennis Kim, Brian Kogon, Matthew E. OsterUsing data from the Pediatric Hospital Information System for 2004 to 2012, the authors compared
the value of transcatheter versus surgical ASD closure for children ages 1 to 17 years. There were
4,606 transcatheter procedures and 3,159 surgeries at 35 children’s hospitals. There was no
mortality. Children with a surgical procedure had a longer length of stay (4.0 days vs. 1.5 days,
p < 0.0001), were more likely to have an infection (odds ratio [OR]: 3.73, p < 0.0001) or
procedural complication (OR: 6.66, p < 0.0001). Costs for transcatheter procedure encounters
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Administration in Chronic Kidney Disease and Congestive Heart Failure Patients89Geng Qian, Zhenhong Fu, Jun Guo, Feng Cao, Yundai ChenHydration before contrast administration is considered the cornerstone of contrast-induced
nephropathy (CIN) prevention. The authors aimed to explore an individual hydration method
for patients with congestive heart failure (CHF) and chronic kidney disease (CKD). These
CHF-complicated CKD patients randomly received either central venous pressure (CVP)-guided
hydration (n ¼ 132) or standard hydration (n ¼ 132). CIN occurred less frequently in CVP-guided
hydration group. The incidence of acute heart failure during the perioperative period did not differ
between the 2 groups. CVP-guided ﬂuid administration can safely and effectively reduce the risk
of CIN in patients with CKD and CHF.n EDITORIAL COMMENT
Improving Intravenous Fluid Therapy for Prevention of Contrast-Induced Nephropathy:
How to Give More Without Causing Heart Failure97Richard Solomon
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